← Back to Home

New Option at First Myeloma Relapse: EU Expands Tecvayli Monotherapy Indication

The threshold for teclistamab monotherapy use in the EU has moved from at least three prior treatments to at least one. A phase 3 trial showed benefits in disease control and survival, but a higher rate of severe infections also makes safety management an important consideration alongside efficacy.

By SURL BioNews

When multiple myeloma relapses after initial treatment, patients often must seek another regimen to control the disease. The European Commission has expanded the monotherapy indication for the bispecific antibody Tecvayli (teclistamab), allowing this immunotherapy, previously used in later lines of treatment, to be used as early as the second line and adding an option for adults experiencing their first relapse.

Johnson & Johnson announced the approval on October 23 for adults with relapsed or refractory multiple myeloma who have received at least one prior treatment. The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive recommendation on September 17 to lower the monotherapy threshold from at least three prior treatments. This change is separate from the indication for teclistamab in combination with daratumumab; monotherapy does not require patients to receive the latter drug.

Teclistamab simultaneously binds to BCMA on the surface of myeloma cells and CD3 on the surface of immune T cells, bringing the two together and prompting T cells to attack cancer cells. The phase 3 MajesTEC-9 trial supporting this approval randomized 593 patients who had received one to three prior lines of treatment to compare teclistamab monotherapy with the physician’s choice of either a three-drug regimen of pomalidomide, bortezomib and dexamethasone, or carfilzomib plus dexamethasone.

At a median follow-up of 17.3 months, the teclistamab group had a 71% lower risk of disease progression or death and a 40% lower risk of death than the control group; these figures describe relative differences in risk during follow-up. Median progression-free survival had not been reached in the teclistamab group, compared with 8.2 months in the control group. This means that the time it would take for half of the patients in the teclistamab group to experience progression or death could not yet be estimated; it does not mean the disease will not progress again.

The efficacy difference was also reflected in outcomes at a fixed time point: at 18 months, 69.8% of patients in the teclistamab group were alive without disease progression, compared with 26.9% in the control group; overall survival rates were 79.2% and 68.6%, respectively. The proportion achieving a complete response or better was 65.9% versus 16.8%, but a complete response still does not equate to a cure.

Stronger disease control was accompanied by an infection burden. According to trial data summarized by OncLive, grade 3 or 4 infections occurred in 41.6% of the teclistamab group and 29.0% of the control group; fatal infections occurred in 5.5% and 2.8%, respectively. Treatment duration differed between the two groups, which must be considered when interpreting cumulative adverse events. However, infection risk remains an important part of evaluating this therapy, and monotherapy should not be regarded as low-risk treatment simply because it uses a single drug.

According to the company’s announcement, the new dosing schedule shifts to once monthly from the seventh month, with eligible patients able to switch as early as the third month, potentially reducing the burden of travel to and from healthcare facilities. However, all trial patients had previously received an anti-CD38 antibody and lenalidomide, and the study did not directly compare all existing second-line options. This approval expands the available treatment options; further data are still needed to clarify the long-term benefits for patients with different treatment histories and the care needs associated with less frequent dosing.

References

  1. Johnson & Johnson EMEA
  2. OncLive
  3. European Medicines Agency
  4. BioSpace (Johnson & Johnson press release)